A Biomet Inc. shareholder filed a lawsuit Jan. 2 in the Supreme Court of the State of New York against the company's board of directors and four private equity firms - Blackstone Group, Kohlberg Kravis Roberts, Texas Pacific Group and Goldman Sachs Capital Partners - to stop a $10.9 billion buyout. The suit claims the buyout consortium's purchase price of $44 per share in cash for each Biomet common share is "an inadequate price." The complaint alleges the directors individually breached their fiduciary duty in approving the sale.
A Biomet Inc. shareholder filed a lawsuit Jan. 2 in the Supreme Court...
Sponsored
White Papers
Sponsored Content
Partner Content